Fructose and (Aging)

Investigation of the Effect of Fructose on Health Parameters and the Intestinal Barrier in Healthy Individuals

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07757347

Acronym

FRUage

Enrollment

Registered

2026-08-11

Start date

2026-04-01

Completion date

2027-12-01

Last updated

2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Response, Intestinal Permeability

Brief summary

The aim of the present study is to investigate the effect of fructose consumption on health parameters and the intestinal barrier in healthy individuals

Interventions

OTHERFructose

Following a standardization of their nutritional intake for three days, participants will either receive a drink supplemented with low doses of free fructose (5%).

OTHERGlucose

Following a standardization of their nutritional intake for three days, participants will either receive a drink supplemented with low doses of free glucose (5 %).

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* all gender, healthy collective ≥ 18 years old

Exclusion criteria

* Chronic inflammatory diseases of the gastrointestinal tract * Metabolic diseases or taking medication to treat metabolic diseases * Fructose malabsorption * Hereditary fructose intolerance * Food intolerances and/or allergies, as well as food allergies that require special dietary interventions * Special diets, such as vegetarian/vegan diets * Unstable body weight within the last 6 months (fluctuations of \> 5%) * BMI \< 19 kg/m2 \& \> 29,9 kg/m2 * Bariatric surgery * Smoking * Liver diseases * Renal insufficiency * Rheumatoid arthritis * COPD with ≥ 2 exacerbations per year * Chronic pancreatitis or recurrent acute pancreatitis * Alcohol consumption above 10 g/d for women and above 20 g/d for men * Pregnancy and breastfeeding * Viral or bacterial infections that occurred no longer than 3 weeks ago

Design outcomes

Primary

Measure	Time frame	Description
Cytokine release from blood immune cells stimulated with bacterial toxins	At the end of the treatment (1 month)	Changes in cytokine concentration in supernatant of immune cells before and after the treatments
Changes in markers of intestinal permeability	At the end of the treatment (1 month)	Changes in concentrations of bacterial endotoxin in blood plasma

Countries

Austria

Contacts

CONTACTIna Bergheim, Prof.

ina.bergheim@univie.ac.at+43-1-4277-54981

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026